- Home
- FRGE vs NLSP Comparison
FRGE vs NLSP Comparison
Compare FRGE & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRGE
- NLSP
- Stock Information
- Founded
- FRGE 2014
- NLSP 2015
- Country
- FRGE United States
- NLSP Switzerland
- Employees
- FRGE N/A
- NLSP N/A
- Industry
- FRGE Computer Software: Prepackaged Software
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- FRGE Technology
- NLSP Health Care
- Exchange
- FRGE Nasdaq
- NLSP Nasdaq
- Market Cap
- FRGE 175.1M
- NLSP 12.4M
- IPO Year
- FRGE N/A
- NLSP 2021
- Fundamental
- Price
- FRGE $16.77
- NLSP $2.10
- Analyst Decision
- FRGE Buy
- NLSP
- Analyst Count
- FRGE 5
- NLSP 0
- Target Price
- FRGE $38.25
- NLSP N/A
- AVG Volume (30 Days)
- FRGE 108.0K
- NLSP 275.3K
- Earning Date
- FRGE 08-06-2025
- NLSP 07-22-2025
- Dividend Yield
- FRGE N/A
- NLSP N/A
- EPS Growth
- FRGE N/A
- NLSP N/A
- EPS
- FRGE N/A
- NLSP N/A
- Revenue
- FRGE $85,383,000.00
- NLSP N/A
- Revenue This Year
- FRGE $18.22
- NLSP N/A
- Revenue Next Year
- FRGE $29.35
- NLSP N/A
- P/E Ratio
- FRGE N/A
- NLSP N/A
- Revenue Growth
- FRGE 16.04
- NLSP N/A
- 52 Week Low
- FRGE $6.60
- NLSP $1.30
- 52 Week High
- FRGE $24.45
- NLSP $15.59
- Technical
- Relative Strength Index (RSI)
- FRGE 48.69
- NLSP 46.61
- Support Level
- FRGE $17.48
- NLSP $2.20
- Resistance Level
- FRGE $19.94
- NLSP $3.08
- Average True Range (ATR)
- FRGE 0.96
- NLSP 0.25
- MACD
- FRGE -0.30
- NLSP -0.06
- Stochastic Oscillator
- FRGE 12.03
- NLSP 8.40
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.